Study of ABT-751 in Patients With Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this
clinical research study is to find the highest safe dose of ABT-751 that can be given as a
treatment for refractory hematologic malignancies. The safety and side effects of ABT-751
will also be studied.